(Q34487161)

2 August 2017

title

Utilization of lipid-lowering drugs in men and women. a reflection of the research evidence? (English)

1 reference

2 August 2017

Isabelle Savoie

1

1 reference

2 August 2017

Arminée Kazanjian

series ordinal

2

1 reference

2 August 2017

publication date

1 January 2002

1 reference

Journal of Clinical Epidemiology

2 August 2017

published in

1 reference

2 August 2017

volume

55

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

95-101

1 reference

Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Recent trends in the consumption of lipid-lowering drugs in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Drug prescription in diabetic patients in Stockholm in 1992 and 1995--change over time

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Descriptive study of lipid-modulating drug use in a French professional population

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Persistence of use of lipid-lowering medications: a cross-national study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

A prescription survey in a hospital hypertension outpatient clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Variations in cholesterol management practices of U.S. physicians.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

A retrospective drug utilization evaluation of antihyperlipidaemic agents in a medical centre in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Effects of "group detailing" on the prescribing of lipid-lowering drugs: a randomized controlled trial in Swedish primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Use of statins in general practices, 1996-8: cross sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Time trend analysis and variations in prescribing lipid lowering drugs in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Do clinical practice guidelines reflect research evidence?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Dyslipoproteinemia in women and the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Should there be a moratorium on the use of cholesterol lowering drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900436-X

7 January 2021

10.1016/S0895-4356(01)00436-X

Identifiers

DOI

1 reference

2 August 2017

1 reference